Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

209.05 -8.94 (-4.10%)
Streaming Delayed Price Updated: 12:05 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 334,446
Open 215.50
Bid (Size) 208.89 (100)
Ask (Size) 209.48 (400)
Prev. Close 217.99
Today's Range 208.52 - 216.25
52wk Range 96.09 - 260.19
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
From Axsome Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+17.0%
+17.0%
1 Month
-13.8%
-13.8%
3 Month
-6.5%
-6.5%
6 Month
+12.5%
+12.5%
1 Year
+96.2%
+96.2%

More News

Read More
News headline image
3 Under-the-Radar Stocks to Buy and Hold ↗
Via The Motley Fool
News headline image
Better Growth Buy: Axsome vs Revolution Medicines ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More ↗
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say. ↗
Via The Motley Fool
News headline image
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗
Via The Motley Fool
News headline image
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline ↗
Via MarketBeat
News headline image
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch ↗
Via MarketBeat
News headline image
3 Stocks Poised to Disrupt the Healthcare Market by 2030 ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Axsome Therapeutics Recognizes Mental Health Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Overlooked Stocks Set to Soar in 2026 ↗
Via The Motley Fool
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Did Axsome Therapeutics Stock Hit Another Record High Today? ↗
Via The Motley Fool
News headline image
Axsome (AXSM) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?
Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?
Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?
The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market
What is the current price of Axsome Therapeutics, Inc. - Common Stock?
The current price of Axsome Therapeutics, Inc. - Common Stock is 209.05
When was Axsome Therapeutics, Inc. - Common Stock last traded?
The last trade of Axsome Therapeutics, Inc. - Common Stock was at 08/03/26 12:05 PM ET
What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?
The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 9.87B
How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?
Axsome Therapeutics, Inc. - Common Stock has 10B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.